Page last updated: 2024-10-18

glycine and Glaucoma, Suspect

glycine has been researched along with Glaucoma, Suspect in 13 studies

Research Excerpts

ExcerptRelevanceReference
"Retinal ischemia increased vitreous concentrations of glutamate and glycine."7.70Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998)
"Retinal ischemia increased vitreous concentrations of glutamate and glycine."3.70Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998)
" Most adverse events (AEs) were mild, and no serious treatment-related AEs were reported."3.01Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. ( Aihara, M; Iwata, A; Kawata, H; Lu, F; Odani-Kawabata, N, 2021)
" However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred dosing frequency for further investigation."3.01A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6). ( Abrams, MA; Chabi, A; Dinh, P; Jerkins, GW; Lu, F; Odani-Kawabata, N; Olander, KW; Sato, MA; Shams, NK, 2021)
"Glaucoma is a main cause of irreversible vision impairment and its prevalence is expected to rise significantly in the near future."2.61Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. ( Barra, F; Cutolo, CA; Ferrero, S; Ferro Desideri, L; Traverso, CE, 2019)
"Patients with glaucoma and ocular hypertension (OH) with no previous history of OMDI use were enrolled."1.72Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan. ( Kuwayama, Y; Nakazawa, T; Nomura, A; Shimada, F; Takahashi, K, 2022)
" The main outcome measures were the change in intraocular pressure (IOP) at week 4 and week 12 after the initiation of OMDI treatment, and frequency of adverse drug reactions."1.72Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan. ( Hori, K; Ishida, N; Miki, A; Miyamoto, E; Shii, D, 2022)
" In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20 μL of either 0."1.48Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. ( Fan, S; Fuwa, M; Ichikawa, M; Iwamura, R; Matsugi, T; Odani-Kawabata, N; Shams, NK; Taniguchi, T; Toris, CB; Yoneda, K; Zhang, JZ, 2018)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (15.38)18.2507
2000's1 (7.69)29.6817
2010's3 (23.08)24.3611
2020's7 (53.85)2.80

Authors

AuthorsStudies
Aihara, M4
Lu, F5
Kawata, H4
Iwata, A4
Odani-Kawabata, N6
Inoue, K1
Shiokawa, M1
Katakura, S1
Tsuruoka, M1
Kunimatsu-Sanuki, S1
Shimizu, K1
Ishida, K1
Tomita, G1
Nakazawa, T1
Takahashi, K1
Kuwayama, Y1
Nomura, A1
Shimada, F1
Miki, A1
Miyamoto, E1
Ishida, N1
Shii, D1
Hori, K1
Shams, NK4
Ropo, A1
Shams, N1
Olander, KW1
Sato, MA1
Abrams, MA1
Jerkins, GW1
Dinh, P1
Chabi, A1
Fuwa, M1
Toris, CB1
Fan, S1
Taniguchi, T1
Ichikawa, M1
Iwamura, R1
Yoneda, K1
Matsugi, T1
Zhang, JZ1
Liu, K1
Ferro Desideri, L1
Cutolo, CA1
Barra, F1
Ferrero, S1
Traverso, CE1
Roe, RH1
Fisher, Y1
Eagle, RC1
Fine, HF1
Cunningham, ET1
Muller, A1
Villain, M1
Bonne, C1
Lagrèze, WA1
Knörle, R1
Bach, M1
Feuerstein, TJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study[NCT02822729]Phase 3125 participants (Actual)Interventional2016-07-01Completed
A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-[NCT02623738]Phase 2/Phase 3253 participants (Actual)Interventional2015-12-06Completed
A Phase III, Open-label, Single-arm, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Who Are Non-/Low-responders to Latanoprost Ophthalmic Solution: FUJ[NCT02822742]Phase 326 participants (Actual)Interventional2016-07-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for glycine and Glaucoma, Suspect

ArticleYear
Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:6

    Topics: Antihypertensive Agents; Glaucoma; Glycine; Humans; Japan; Ocular Hypertension; Pyrazoles; Pyridines

2019

Trials

6 trials available for glycine and Glaucoma, Suspect

ArticleYear
Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Japanese journal of ophthalmology, 2021, Volume: 65, Issue:6

    Topics: Antihypertensive Agents; Double-Blind Method; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pre

2021
Periocular Adverse Reactions to Omidenepag Isopropyl.
    American journal of ophthalmology, 2022, Volume: 237

    Topics: Antihypertensive Agents; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressure; Ocular Hyperte

2022
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
    American journal of ophthalmology, 2020, Volume: 220

    Topics: Dose-Response Relationship, Drug; Female; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressur

2020
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Japanese journal of ophthalmology, 2020, Volume: 64, Issue:4

    Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Glycine; Hu

2020
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
    Journal of glaucoma, 2021, 06-01, Volume: 30, Issue:6

    Topics: Antihypertensive Agents; Double-Blind Method; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pre

2021
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Journal of glaucoma, 2019, Volume: 28, Issue:5

    Topics: Aged; Antihypertensive Agents; Corneal Pachymetry; Dose-Response Relationship, Drug; Double-Blind Me

2019

Other Studies

6 other studies available for glycine and Glaucoma, Suspect

ArticleYear
Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Advances in therapy, 2022, Volume: 39, Issue:3

    Topics: Antihypertensive Agents; Glaucoma; Glaucoma, Open-Angle; Glycine; Humans; Intraocular Pressure; Japa

2022
Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
    Advances in therapy, 2022, Volume: 39, Issue:5

    Topics: Antihypertensive Agents; Drug-Related Side Effects and Adverse Reactions; Glaucoma; Glaucoma, Open-A

2022
Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2018, Volume: 34, Issue:7

    Topics: Administration, Topical; Animals; Aqueous Humor; Dose-Response Relationship, Drug; Female; Glycine;

2018
Oculoleptomeningeal amyloidosis in a patient with a TTR Val30Gly mutation in the transthyretin gene.
    Ophthalmology, 2007, Volume: 114, Issue:11

    Topics: Adult; Amyloid; Amyloid Neuropathies, Familial; DNA Mutational Analysis; Eye Diseases; Glycine; Huma

2007
The release of amino acids from ischemic retina.
    Experimental eye research, 1997, Volume: 64, Issue:2

    Topics: Alanine; Amino Acids; Animals; Glutamic Acid; Glycine; Ischemia; Male; Ocular Hypertension; Rabbits;

1997
Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia.
    Investigative ophthalmology & visual science, 1998, Volume: 39, Issue:6

    Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Excitatory Amino

1998